DekaBank Deutsche Girozentrale
CHRS icon

DekaBank Deutsche Girozentrale’s Coherus Oncology CHRS Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-120,000
Closed -$498K – 1496
2023
Q2 		$498K Buy
120,000
+3,400
+3% +$20.1K ﹤0.01% 1027
2023
Q1 		$737K Hold
116,600
– – ﹤0.01% 938
2022
Q4 		$840K Hold
116,600
– – ﹤0.01% 924
2022
Q3 		$1.07M Hold
116,600
– – ﹤0.01% 862
2022
Q2 		$843K Hold
116,600
– – ﹤0.01% 915
2022
Q1 		$1.5M Buy
116,600
+10,600
+10% +$135K ﹤0.01% 824
2021
Q4 		$1.8M Buy
106,000
+2,900
+3% +$50.7K ﹤0.01% 798
2021
Q3 		$1.69M Buy
103,100
+30,000
+41% +$440K ﹤0.01% 758
2021
Q2 		$1.02M Hold
73,100
– – ﹤0.01% 904
2021
Q1 		$1.07M Buy
73,100
+35,000
+92% +$594K ﹤0.01% 886
2020
Q4 		$645K Sell
38,100
-1,900
-5% -$33.8K ﹤0.01% 970
2020
Q3 		$733K Buy
+40,000
New +$744K ﹤0.01% 845
2019
Q4 		– Sell
-41,400
Closed -$848K – 1154
2019
Q3 		$848K Sell
41,400
-44,000
-52% -$879K 0.01% 700
2019
Q2 		$1.83M Buy
85,400
+64,100
+301% +$1.11M 0.01% 643
2019
Q1 		$426K Buy
21,300
+3,600
+20% +$48K ﹤0.01% 932
2018
Q4 		$156K Sell
17,700
-3,600
-17% -$41.7K ﹤0.01% 1003
2018
Q3 		$426K Sell
21,300
-600
-3% -$10.6K ﹤0.01% 954
2018
Q2 		$323K Hold
21,900
– – ﹤0.01% 985
2018
Q1 		$245K Sell
21,900
-500
-2% -$5.47K ﹤0.01% 967
2017
Q4 		$258K Hold
22,400
– – ﹤0.01% 917
2017
Q3 		$258K Hold
22,400
– – ﹤0.01% 923
2017
Q2 		$324K Hold
22,400
– – ﹤0.01% 892
2017
Q1 		$459K Buy
+22,400
New +$551K ﹤0.01% 748
2016
Q3 		– Sell
-22,400
Closed -$376K – 971
2016
Q2 		$376K Buy
22,400
+5,700
+34% +$107K ﹤0.01% 735
2016
Q1 		$321K Buy
+16,700
New +$274K ﹤0.01% 743

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

DekaBank Deutsche Girozentrale's CHRS Position: Q3 2023 in Review

DekaBank Deutsche Girozentrale sold out of Coherus Oncology (CHRS) in Q3 2023, closing a stake of 120,000 shares — an estimated $498K sold.

DekaBank Deutsche Girozentrale first reported a position in CHRS in Q1 2016 and held it in 25 quarters. The position peaked at $1.83M in Q2 2019. 169 funds tracked by Wall St. Rank hold CHRS as of Q3 2023.

  • DekaBank Deutsche Girozentrale reported no remaining Coherus Oncology position as of Q3 2023 after selling out during the quarter.
  • DekaBank Deutsche Girozentrale sold 120,000 Coherus Oncology shares in Q3 2023, an estimated $498K.
  • DekaBank Deutsche Girozentrale first reported a position in Coherus Oncology in Q1 2016 and held it in 25 quarters.
  • DekaBank Deutsche Girozentrale's Coherus Oncology position peaked at $1.83M in Q2 2019.
  • 169 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2023.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q3 2023, filed 13 Nov 2023.